We are a research and analytics company with a strong team of analysts focused in the area of cancer and oncology. We analyse marketed as well as pipeline drugs used in the treatment of various types of cancer across different therapy classes, while considering their regulatory approval timelines. Additionally, we also provide company-specific research for these drugs. We have an extensive coverage of 250+ marketed drugs, 1000+ pipeline drugs, 200+ cancer types and 300+ companies spanning across USD 95 bn+ oncology drug market.(a) Marketed drugs: Our exhaustive coverage of 250+ marketed drugs (which forms the USD 95 bn+ market and are almost all of the approved drugs irrespective of size) includes "star" drugs (those with USD 5 bn+ revenue), drugs with negligible or zero sales and discontinued drugs(b) Pipeline drugs: Our coverage of 1000+ pipeline drugs primarily focuses on commercial opportunities in the next five years and emerging class of drugs(c) Therapy classes: We have classified cancer treatment into two main segments: Core oncology (84% of total sales) and supportive care (adjuvants; 16% of total sales). Core oncology is further classified into the following: Targeted therapy, hormone therapy, chemotherapy and vaccines (immuno-oncology dominates targeted therapy and is also included in vaccines)(d) Cancer types: Solid tumors (lung cancer, breast, colo-rectal, skin, brain, etc) and hematological cancers (lymphoma, leukemia, myeloma, etc)(e) Regulatory approvals: We carry out analysis of approvals from the three main regulatory authorities, viz., USFDA (US), EMA (Europe) and PMDA (Japan). (f) Our coverage universe: 300+ pharmaceutical companies (large/mid/small; listed/unlisted)